

AMENDMENTS TO THE CLAIMS

1-2. (canceled)

3. (previously presented) An isolated antibody that selectively binds to a polypeptide, wherein the amino acid sequence of said polypeptide consists of SEQ ID NO:2.

4-11. (canceled)

12. (withdrawn) A method for detecting a polypeptide in a sample, wherein the polypeptide has an amino acid sequence consisting of SEQ ID NO:2, and wherein the method comprises:

- (a) contacting the sample with an antibody that selectively binds to the polypeptide; and
- (b) detecting the binding of the antibody to the polypeptide to thereby detect the polypeptide.

13-23. (canceled)

24. (withdrawn) A method for detecting a polypeptide in a sample, wherein the polypeptide has an amino acid sequence comprising SEQ ID NO:2, and wherein the method comprises:

- (a) contacting the sample with an antibody that selectively binds to the polypeptide; and
- (b) detecting the binding of the antibody to the polypeptide to thereby detect the polypeptide.

25. (withdrawn) The method of claim 12, wherein the antibody is coupled to a detectable substance.

26. (withdrawn) The method of claim 24, wherein the antibody is coupled to a detectable substance.
27. (previously presented) An isolated antibody that selectively binds to a polypeptide, wherein the amino acid sequence of said polypeptide comprises SEQ ID NO:2.
28. (previously presented) The antibody of claim 3, wherein the antibody is a monoclonal antibody.
29. (previously presented) The antibody of claim 27, wherein the antibody is a monoclonal antibody.
30. (previously presented) The antibody of claim 3, wherein the antibody is coupled to a detectable substance.
31. (previously presented) The antibody of claim 27, wherein the antibody is coupled to a detectable substance.
32. (previously presented) The antibody of claim 28, wherein the antibody is coupled to a detectable substance.
33. (previously presented) The antibody of claim 29, wherein the antibody is coupled to a detectable substance.
34. (previously presented) A composition comprising the antibody of claim 3 and a pharmaceutically acceptable carrier.
35. (previously presented) A composition comprising the antibody of claim 27 and a pharmaceutically acceptable carrier.

36. (previously presented) A composition comprising the antibody of claim 28 and a pharmaceutically acceptable carrier.

37. (previously presented) A composition comprising the antibody of claim 29 and a pharmaceutically acceptable carrier.

38. (previously presented) An isolated antibody fragment that selectively binds to a polypeptide, wherein the amino acid sequence of said polypeptide consists of SEQ ID NO:2, and wherein the antibody fragment comprises a fragment selected from the group consisting of:

- a) an Fab fragment;
- b) an $F(ab')_2$ fragment; and
- c) an Fv fragment.

39. (previously presented) An isolated antibody fragment that selectively binds to a polypeptide, wherein the amino acid sequence of said polypeptide comprises SEQ ID NO:2, and wherein the antibody fragment comprises a fragment selected from the group consisting of:

- a) an Fab fragment;
- b) an $F(ab')_2$ fragment; and
- c) an Fv fragment.